FDA Approval Summary: Niraparib for the Maintenance Treatment of Patients with Recurrent Ovarian Cancer in Response to Platinum-Based Chemotherapy - Ison, G., Howie, L. J., Amiri-Kordestani, L., Zhang, L., Tang, S., Sridhara, R., Pierre, V., Charlab, R., Ramamoorthy, A., Song, P., Li, F., Yu, J., Manheng, W., Palmby, T. R., Ghosh, S., Horne, H. N., Lee, E. Y., Philip, R., Dave, K., Chen, X. H., Kelly, S. L., Janoria, K. G., Banerjee, A., Eradiri, O., Dinin, J., Goldberg, K. B., Pierce, W. F., Ibrahim, A., Kluetz, P. G., Blumenthal, G. M., Beaver, J. A., Pazdur, R. (The American Association for Cancer Research (AACR), 2018)
6327872
Keywords: WW-YZ